PSMA-PET/CT influenced clinical management in 72% (13/18) of patients restaged after radiation therapy (not reaching a biochemical recurrence), 67% (8/12) of those evaluated following other definitive local treatments, and 61% (59/96) of patients with advanced metastatic disease. This evidence concerns the gene FOLH1 and metastatic neoplasm.